KR20100100496A - 온도 민감성 풀루란-락타이드 공중합체, 이로부터 형성된 나노입자, 및 그 제조방법 - Google Patents
온도 민감성 풀루란-락타이드 공중합체, 이로부터 형성된 나노입자, 및 그 제조방법 Download PDFInfo
- Publication number
- KR20100100496A KR20100100496A KR1020090019416A KR20090019416A KR20100100496A KR 20100100496 A KR20100100496 A KR 20100100496A KR 1020090019416 A KR1020090019416 A KR 1020090019416A KR 20090019416 A KR20090019416 A KR 20090019416A KR 20100100496 A KR20100100496 A KR 20100100496A
- Authority
- KR
- South Korea
- Prior art keywords
- pullulan
- lactide
- nanoparticles
- drug
- temperature
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
풀루란의 말토오즈 1 유닛당 결합된 락타이드의 양 | |
PUPL1 | 0.81 |
PUPL2 | 0.87 |
PUPL3 | 1.42 |
Claims (10)
- 풀루란 및 락타이드가 에스테르 결합에 의해 공중합되어 형성되는, 온도 민감성 풀루란-락타이드 공중합체.
- 제 1 항에 있어서, 상기 풀루란의 트리말토오스 1 유닛당 락타이드의 결합 분자수 0.5 내지 12.0의 비율로 공중합되는 것을 특징으로 하는 온도 민감성 풀루란-락타이드 공중합체.
- 풀루란 및 락타이드를 용매 중에 용해하는 단계;상기 풀루란과 락타이드의 혼합용액을 풀루란에 락타이드가 충분히 결합되도록 교반하여 반응시키는 단계; 및상기 반응물을 투석막에 넣고 수중에서 투석에 의해 용매, 미반응물, 및 불순물을 제거하는 단계를 포함하는 제1항 또는 제2항에 따른 온도 민감성 풀루란-락타이드 공중합체를 제조하는 방법.
- 제 3 항에 있어서, 상기 풀루란 및 락타이드를 용매 중에 용해하는 단계에서, 풀루란의 글루코오스 단량체의 락타이드 분자에 대한 비율이 1:1.8 내지 1:2.2의 비율이 되도록 풀루란 및 락타이드를 용해하는 것을 특징으로 하는 방법.
- 제 4 항에 있어서, 풀루란과 락타이드를 용매 중에 용해하는 단계에서, 트리에틸아민, 스테노우스 옥테이트(Stanous octate)을 촉매로서 더 가하는 것을 특징으로 하는 방법.
- 제1항에 따른 풀루란-락타이드 공중합체 및 약물 포함하고, 온도의 변화에 따라 풀루란-락타이드 공중합체가 자기집합에 의해 나노입자를 형성하고 약물이 그 나노입자에 봉입되는 온도 민감성 나노입자.
- 제6항에 있어서, 상기 약물은 소수성 약물인 것을 특징으로 하는 온도 민감성 나노입자.
- 제7항에 있어서, 상기 소수성 약물은 독소루비신, 탁솔, 캄토테신, 아드리아마이신, 파클리탁셀, 시스플라틴(cis-platin), 미토마이신-C, 도노마이신(daunomycin), 포피린 (porphyrin) 유도체, 클로린 (chlorine) 유도체, 및 5-플루오로우라실(5-fluorouracil)로 구성된 그룹에서 선택되는 것을 특징으로 하는 온도 민감성 나노입자.
- 제1항에 따른 풀루란-락타이드 공중합체 및 약물을 용매에 용해하는 단계;상기 풀루란-락타이드 공중합체 용액을 투석막에 넣고 수중에서 투석함으로써 물이 투석막 내부로 유입되면서 풀루란-락타이드 공중합체가 자기집합되어 나노 입자를 형성하는 단계; 및상기 형성된 나노입자를 동결건조하여 나노입자를 회수하는 단계를 포함하는, 제6항 내지 제8항 중 어느 한 항에 따른 나노입자를 제조하는 방법.
- 제6항 내지 제8항 중 어느 한 항에 따른 나노입자를 포함하는 주사제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090019416A KR101086055B1 (ko) | 2009-03-06 | 2009-03-06 | 온도 민감성 풀루란-락타이드 공중합체, 이로부터 형성된 나노입자, 및 그 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090019416A KR101086055B1 (ko) | 2009-03-06 | 2009-03-06 | 온도 민감성 풀루란-락타이드 공중합체, 이로부터 형성된 나노입자, 및 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100100496A true KR20100100496A (ko) | 2010-09-15 |
KR101086055B1 KR101086055B1 (ko) | 2011-11-22 |
Family
ID=43006568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090019416A KR101086055B1 (ko) | 2009-03-06 | 2009-03-06 | 온도 민감성 풀루란-락타이드 공중합체, 이로부터 형성된 나노입자, 및 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101086055B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101419124B1 (ko) * | 2011-09-16 | 2014-07-11 | 가톨릭대학교 산학협력단 | 폴리에틸렌옥사이드-폴리프로필렌옥사이드 블록공중합체와 광감작제가 공유 결합된 광역학 치료용 복합체 |
US10568839B2 (en) | 2011-01-11 | 2020-02-25 | Capsugel Belgium Nv | Hard capsules |
US11319566B2 (en) | 2017-04-14 | 2022-05-03 | Capsugel Belgium Nv | Process for making pullulan |
US11576870B2 (en) | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07116268B2 (ja) | 1984-01-09 | 1995-12-13 | 大西 靖彦 | デキストランの陰イオン性部分置換体とオレフィン化合物との共重合体の製法 |
ES2355186T3 (es) | 1997-09-05 | 2011-03-23 | Maruho K.K. | Preparaciones de nanocápsulas para tratar enfermedades intraarticulares. |
-
2009
- 2009-03-06 KR KR1020090019416A patent/KR101086055B1/ko active IP Right Grant
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10568839B2 (en) | 2011-01-11 | 2020-02-25 | Capsugel Belgium Nv | Hard capsules |
KR101419124B1 (ko) * | 2011-09-16 | 2014-07-11 | 가톨릭대학교 산학협력단 | 폴리에틸렌옥사이드-폴리프로필렌옥사이드 블록공중합체와 광감작제가 공유 결합된 광역학 치료용 복합체 |
US11319566B2 (en) | 2017-04-14 | 2022-05-03 | Capsugel Belgium Nv | Process for making pullulan |
US11576870B2 (en) | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
US11878079B2 (en) | 2017-04-14 | 2024-01-23 | Capsugel Belgium Nv | Pullulan capsules |
Also Published As
Publication number | Publication date |
---|---|
KR101086055B1 (ko) | 2011-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Injectable, NIR/pH-responsive nanocomposite hydrogel as long-acting implant for chemophotothermal synergistic cancer therapy | |
Zhang et al. | A pH-sensitive nanosystem based on carboxymethyl chitosan for tumor-targeted delivery of daunorubicin | |
Hu et al. | Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals | |
Liu et al. | Injectable, biodegradable, thermosensitive nanoparticles-aggregated hydrogel with tumor-specific targeting, penetration, and release for efficient postsurgical prevention of tumor recurrence | |
Rejinold et al. | Biodegradable and thermo-sensitive chitosan-g-poly (N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier | |
Wu et al. | Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer | |
TWI306869B (en) | Amphiphilic block copolymers and nano particles comprising the same | |
Sun et al. | Temperature-sensitive gold nanoparticle-coated pluronic-PLL nanoparticles for drug delivery and chemo-photothermal therapy | |
Jia et al. | Unimolecular micelles of amphiphilic cyclodextrin-core star-like copolymers with covalent pH-responsive linkage of anticancer prodrugs | |
Zhan et al. | An injectable hydrogel with pH-sensitive and self-healing properties based on 4armPEGDA and N-carboxyethyl chitosan for local treatment of hepatocellular carcinoma | |
CN105963706B (zh) | 一种支化hpma共聚物-dox偶联物及其制备方法和应用 | |
Zhu et al. | Responsive hydrogels based on triggered click reactions for liver cancer | |
Ke et al. | Length effect of stimuli-responsive block copolymer prodrug filomicelles on drug delivery efficiency | |
CN101254309A (zh) | 叶酸受体介导靶向乙酰普鲁兰多糖纳米粒及制备方法 | |
CN103656652B (zh) | 一种双敏感响应型聚合物纳米胶束及其制备方法和应用 | |
Chen et al. | Poly (N-isopropylacrylamide) derived nanogels demonstrated thermosensitive self-assembly and GSH-triggered drug release for efficient tumor Therapy | |
An et al. | An acid-triggered degradable and fluorescent nanoscale drug delivery system with enhanced cytotoxicity to cancer cells | |
CN104888235A (zh) | 具有共递送多个药物的pH敏感纳米粒前药及其制备方法与应用 | |
Senthilkumar et al. | Conjugated polymer nanogel binding anticancer drug through hydrogen bonds for sustainable drug delivery | |
Wang et al. | Nano micelles of cellulose-graft-poly (l-lactic acid) anchored with epithelial cell adhesion antibody for enhanced drug loading and anti-tumor effect | |
Xue et al. | Self-assembly of affinity-controlled nanoparticles via host–guest interactions for drug delivery | |
Soleimani et al. | Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma | |
Zhu et al. | Peptidic monodisperse PEG “combs” with fine-tunable LCST and multiple imaging modalities | |
KR101086055B1 (ko) | 온도 민감성 풀루란-락타이드 공중합체, 이로부터 형성된 나노입자, 및 그 제조방법 | |
CN108310395A (zh) | 一种表面电荷可转换的聚合物纳米药物载体及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151111 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161025 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171020 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181016 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191025 Year of fee payment: 9 |